TAINAN, Taiwan, Aug. 31 ScinoPharm, a leading activepharmaceutical ingredient (API) developer and manufacturer headquartered inTaiwan, today announced an investment into Tanvex Biologics, Inc., a UnitedStates company registered in the State of Delaware. ScinoPharm's investmentwas in the form of tangible assets, intellectual properties, as well as cash.
Tanvex specializes in the development of biosimilars and biobetters, aswell as the provision of contract research and contract manufacturing servicesfor biologics. The company is currently establishing a cGMP facility in SanDiego, California and will have research centers in both the U.S. and Taiwan.Tanvex is founded by Dr. Allen Chao, the founder and former Chairman and ChiefExecutive Officer of Watson Pharmaceuticals, Inc.
Dr. Hardy Chan, co-founder and Chief Scientific Officer of ScinoPharm,will become the Chief Executive Officer of Tanvex. Dr. Chao will remain asExecutive Chairman of Tanvex.
About ScinoPharm Taiwan
ScinoPharm Taiwan, Ltd. is a leading process R&D and API manufacturingservice provider to the global pharmaceutical industry. With research andmanufacturing facilities in both Taiwan and mainland China, ScinoPharm offersa wide portfolio of services ranging from custom synthesis for early phasepharmaceutical activities to brand companies as well as APIs for the genericindustry. For more information, please visit http://www.scinopharm.com .
About Tanvex Biologics
Tanvex Biologics, LLC is a US-based biopharmaceutical company specializingin the development of biopharmaceuticals.Media Contact: ScinoPharm Taiwan, Ltd. Sabrian Wu Tel: +886-6-505-2869 Mobile Phone: +886-920-056-385 Email: email@example.com
SOURCE ScinoPharm Taiwan, Ltd.